Kiora Pharmaceuticals (NASDAQ:KPRX) Issues Earnings Results

Kiora Pharmaceuticals (NASDAQ:KPRX) announced its earnings results on Friday. The company reported ($0.58) EPS for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.13, FiscalAI reports.

Kiora Pharmaceuticals Stock Performance

Kiora Pharmaceuticals stock remained flat at $2.45 during trading hours on Friday. 40,835 shares of the company’s stock were exchanged, compared to its average volume of 64,626. The company has a market capitalization of $10.85 million, a P/E ratio of -0.92 and a beta of -0.48. The stock has a 50 day moving average of $2.21 and a 200 day moving average of $2.17. Kiora Pharmaceuticals has a fifty-two week low of $1.76 and a fifty-two week high of $4.18.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Kiora Pharmaceuticals in a report on Monday, April 27th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $10.00.

Institutional Investors Weigh In On Kiora Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the business. Two Sigma Investments LP acquired a new position in shares of Kiora Pharmaceuticals during the third quarter valued at about $33,000. Citadel Advisors LLC acquired a new position in shares of Kiora Pharmaceuticals during the third quarter valued at about $125,000. Renaissance Technologies LLC increased its holdings in shares of Kiora Pharmaceuticals by 71.0% during the fourth quarter. Renaissance Technologies LLC now owns 21,200 shares of the company’s stock valued at $42,000 after acquiring an additional 8,800 shares in the last quarter. DRW Securities LLC increased its holdings in shares of Kiora Pharmaceuticals by 199.2% during the fourth quarter. DRW Securities LLC now owns 110,282 shares of the company’s stock valued at $217,000 after acquiring an additional 73,417 shares in the last quarter. Finally, Alyeska Investment Group L.P. acquired a new position in shares of Kiora Pharmaceuticals during the fourth quarter valued at about $152,000. Institutional investors and hedge funds own 76.97% of the company’s stock.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc (NASDAQ: KPRX) is a clinical-stage biotechnology company dedicated to developing innovative therapies for serious eye diseases. The company’s research efforts focus on modulating immune and neurological pathways in the eye to address conditions that currently have limited treatment options. Kiora’s approach combines small-molecule immunomodulators with advanced gene-based and optogenetic technologies to preserve and restore vision.

The company’s lead product candidate, KIO-100 (PP-001), is an intravitreal formulation designed to inhibit key inflammatory pathways implicated in non-infectious uveitis and other autoimmune ocular disorders.